FDA Adverse Event Injury Summary report: N

ON-Q PAINBUSTER

MDR report key: 2762482 · Received September 24, 2012

Report

Report Number
2026095-2012-00234
Event Type
Injury
Date Received
September 24, 2012
Date of Event
March 8, 2004
Report Date
August 24, 2012
Manufacturer
I-FLOW, LLC
Product Code
MEB
PMA / PMN Number
K063530
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
NOT APPLICABLE

Narratives

Additional Manufacturer Narrative · 1

METHOD: NO PRODUCT WAS RETURNED FOR EVAL AND INVESTIGATION. THE LOT NUMBER WAS NOT PROVIDED; THEREFORE THE DEVICE HISTORY RECORDS COULD NOT BE REVIEWED. RESULT: THE INFO CONTAINED IS FROM LEGAL DOCUMENTS SERVED ON I-FLOW, LLC. THE COMPLAINT WAS OPENED SO THAT A MEDICAL DEVICE REPORT (MDR) CAN BE FILED WITH THE U.S. FOOD AND DRUG ADMINISTRATION. NO FURTHER INVESTIGATION WILL BE CONDUCTED. CONCLUSION: AS THIS COMPLAINT WAS CREATED FROM A LAWSUIT SERVED ON I-FLOW OR THE THREAT OF A LAWSUIT, NO CUSTOMER CONTACT CAN BE MADE AT THIS TIME DUE TO THE PENDING OR THREATENED LITIGATION." AS OF 11/09/2006, I-FLOW UPDATED THE ON-Q PUMP DIRECTIONS FOR USE (DFU), TO INCLUDE THE FOLLOWING IN THE WARNINGS SECTION: "AVOID PLACING THE CATHETER IN JOINT SPACES. ALTHOUGH THERE IS NO DEFINITIVE ESTABLISHED CAUSAL RELATIONSHIP, SOME LITERATURE HAS SHOWN A POSSIBLE ASSOCIATION BETWEEN CONTINUOUS INTRA-ARTICULAR INFUSIONS (PARTICULARLY WITH BUPIVACAINE) AND THE SUBSEQUENT DEVELOPMENT OF CHONDROLYSIS." (DFU 1307011). ON 08/08/2007, I-FLOW HAS ALSO PREPARED A TECHNICAL BULLETIN ENTITLED "WHAT WE KNOW ABOUT CHONDROLYSIS TODAY". (1303722, REV E).

Description of Event or Problem · 1

DRUG/DILUENT: UNK, FILL VOLUME: UNK, FLOW RATE: UNK, PROCEDURE: RIGHT SHOULDER SURGERY, CATHPLACE: RIGHT SHOULDER. PT ALLEGES DEGENERATION OF SHOULDER CARTILAGE FOLLOWING PLACEMENT OF AN ON-Q PAINBUSTER PUMP AFTER SURGERY ON (B)(6), 2004.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ON-Q PAINBUSTER ELASTOMERIC PUMP MEB I-FLOW, LLC UNK UNK

Patients

Seq Age Sex Outcome Treatment
1 40 YR Other